| Literature DB >> 18939877 |
Alison C Donnelly1, Jared R Mays, Joseph A Burlison, John T Nelson, George Vielhauer, Jeffrey Holzbeierlein, Brian S J Blagg.
Abstract
Novobiocin, a known DNA gyrase inhibitor, binds to a nucleotide-binding site located on the Hsp90 C-terminus and induces degradation of Hsp90-dependent client proteins at approximately 700 microM in breast cancer cells (SKBr3). Although many analogues of novobiocin have been synthesized, it was only recently demonstrated that monomeric species exhibit antiproliferative activity against various cancer cell lines. To further refine the essential elements of the coumarin core, a series of modified coumarin derivatives was synthesized and evaluated to elucidate structure-activity relationships for novobiocin as an anticancer agent. Results obtained from these studies have produced novobiocin analogues that manifest low micromolar activity against several cancer cell lines.Entities:
Mesh:
Substances:
Year: 2008 PMID: 18939877 PMCID: PMC2646372 DOI: 10.1021/jo801312r
Source DB: PubMed Journal: J Org Chem ISSN: 0022-3263 Impact factor: 4.354